14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AKTS vs SPRO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Spero Therapeutics, Inc. (SPRO) is the stronger overall head-to-head candidate over AKTS (AKTS) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKTS carries a Unified Composite Score of 30.6/100 (SELL) at $16.55 (N/M Forward P/E, N/A operating margin), whereas SPRO carries 47.8/100 (HOLD) at $0.92 (N/M Forward P/E, 14.1% operating margin).
Technical & Structure Timing Caution: AKTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.1); meanwhile SPRO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKTS vs SPRO. Trailing 12-month operating profitability (AKTS N/A vs SPRO 14.1%) and valuation multiples (AKTS N/M vs SPRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $58.8M market capitalization and 14.1% operating margin.
OpEx & R&D Reinvestment42.2% of Rev ($20M)
90D Engineering Disclosures0 Published
Investor FAQ AKTS vs SPRO Key Questions & Quantitative Answers
As of Nov 16, 2026, Spero Therapeutics, Inc. (SPRO) is the stronger overall head-to-head candidate over AKTS (AKTS) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKTS carries a Unified Composite Score of 30.6/100 (SELL) at $16.55 (N/M Forward P/E, N/A operating margin), whereas SPRO carries 47.8/100 (HOLD) at $0.92 (N/M Forward P/E, 14.1% operating margin). Technical & Structure Timing Caution: AKTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.1); meanwhile SPRO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SPRO leads the Growth & Scale pillar: AKTS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with SPRO at -95.6% YoY revenue growth and +75.3% YoY earnings growth on $47M TTM revenue (56.3% gross margin, 14.1% operating margin). On trailing 12-month operating scale, AKTS generates N/A in USD-normalized revenue versus $47M for SPRO. In operating R&D and SG&A reinvestment, AKTS deploys N/A (0 90-day corporate R&D disclosures) versus 42.2% of Rev ($20M) (0 disclosures) for SPRO.
SPRO screens cheaper on headline valuation multiples. AKTS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SPRO trades at N/M Forward P/E, 7.2x Trailing P/E, N/M PEG, and 0.2x EV/Revenue (41.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKTS (N/A ROE) versus SPRO (19.2% ROE) capital efficiency.
In options market volatility and institutional positioning, AKTS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.35β · 67% Vol realized risk). By comparison, SPRO carries 114.8% implied volatility (24th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.75β · 70% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.